Inflammatory Bowel Diseases

Skip Navigation LinksHome > March 2013 - Volume 19 - Issue 3 > Risk of Extraintestinal Solid Cancer with Anti-TNF Therapy i...
Inflammatory Bowel Diseases:
doi: 10.1097/MIB.0b013e318280ebbd
Clinical Reviews

Risk of Extraintestinal Solid Cancer with Anti-TNF Therapy in Adults with Inflammatory Bowel Disease: Review of the Literature

Hudesman, David MD*; Lichtiger, Simon MD; Sands, Bruce MD

Collapse Box


Absract: With the increased use of anti-TNF therapy for both ulcerative colitis and Crohn’s disease, there is serious concern about long term adverse events, especially malignancy. Recent data suggests that anti-TNF agents increase the risk of non-Hodgkin’s lymphoma; however, there is limited evidence on the risk of solid tumors. Many patients have been exposed to other immunosuppressive therapies in the past making it difficult to discern the true risk of malignancy with TNF-alpha inhibitors alone. The purpose of this review is to discuss the risk of extra-intestinal solid cancer, excluding skin cancer, in adult inflammatory bowel disease patients exposed to anti-TNF agents.

© Crohn's & Colitis Foundation of America, Inc.

You currently do not have access to this article.

You may need to:

Note: If your society membership provides for full-access to this article, you may need to login on your society’s web site first.


Article Tools


Article Level Metrics